Stock listing

Lang & Schwarz:A1JUH2 Ryvu Therapeutics SA Aktie

German listing (Lang & Schwarz) of Ryvu Therapeutics SA · home listing GPW:RVU

Follow Ryvu Therapeutics SA into a list and get an email when it puts out news.

Home listing price · GPW:RVU

16.98 PLN -0.82 (-4.6%)

Close on Oct 30, 2026 · This listing has no price on 6ix; the price shown is the home listing's, GPW:RVU

Past year -30.1% · daily closes, Oct 30, 2025 – Oct 30, 2026, adjusted for splits
Day range
16.52 – 17.86 PLNOct 30, 2026
Volume
75,603 sharesOct 30, 2026
Market cap
392.6M PLNAt the close on Oct 30, 2026 · price × 23.12M shares outstanding
52-week range
13.64 – 31.90 PLNLowest and highest trades, Oct 31, 2025 – Oct 30, 2026
Traded on an average day
572,991 PLNMedian day 21,035 shares · last 3 months, Jul 30, 2026 – Oct 30, 2026
Ryvu Therapeutics SA logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
GPW:RVU · Home16.98 PLN-0.82 (-4.6%)75,60317.8017.8616.5217.80Close on Oct 30, 2026
Frankfurt:9Y4€3.945 EUR-0.085 (-2.1%)—€3.945€3.945€3.945€4.03Close on Oct 30, 2026

Daily closes

Last 3 months, Jul 30, 2026 – Oct 30, 2026 · GPW:RVU · PLN, adjusted for splits

DayCloseChange%OpenHighLowVolume
16.98-0.82-4.6%17.8017.8616.5275,603
17.80-0.42-2.3%18.0218.4417.5238,748
18.22-0.38-2.0%18.7818.7818.0420,710
18.60-0.06-0.3%18.7818.8618.0025,417
18.66+0.88+4.9%17.9618.9017.78125,376
17.78+0.08+0.5%17.7017.9817.4037,101
17.70+0.32+1.8%17.5218.0217.3429,651
17.38+0.32+1.9%17.0617.8817.0612,759
17.06-0.74-4.2%17.9017.9016.8017,474
17.80-0.24-1.3%18.0818.0816.2827,023
18.04+0.60+3.4%17.3018.0617.3040,385
17.44+0.54+3.2%17.8017.9017.2228,966
16.90-0.30-1.7%17.1017.1816.6017,891
17.20+0.06+0.4%17.3817.5016.9827,088
17.14+0.64+3.9%16.6217.1816.5217,560
16.50+0.22+1.4%16.3016.6016.2014,498
16.28+0.22+1.4%16.1416.3616.0011,999
16.06+0.08+0.5%16.1016.3015.8019,528
15.98+0.18+1.1%15.8016.0015.665,930
15.80+0.30+1.9%16.0016.0015.445,928
15.50-0.12-0.8%15.5815.6615.489,673
15.62-0.02-0.1%15.9016.0015.547,133
15.64-0.26-1.6%16.0016.0015.627,803
15.90-0.18-1.1%16.0816.0815.628,372
16.08+0.14+0.9%16.0216.1415.869,037
15.94+0.02+0.1%15.9216.1015.748,764
15.92+0.08+0.5%15.8415.9815.708,645
15.84-0.16-1.0%16.1016.2015.8213,162
16.00+0.10+0.6%16.0016.1815.8615,979
15.90+0.10+0.6%16.2016.3415.8234,914
15.80-0.52-3.2%16.3216.9815.6055,241
16.32-0.38-2.3%16.6216.7616.0228,245
16.700.000.0%16.7616.7616.507,545
16.70-0.28-1.6%16.9416.9416.6029,588
16.98-0.06-0.4%17.0617.1816.944,710
17.04-0.32-1.8%17.3017.3816.9818,452
17.36-0.24-1.4%17.5217.6017.0216,745
17.60-0.30-1.7%17.9818.4217.6035,690
17.90+0.58+3.3%17.5017.9217.3625,003
17.32+0.24+1.4%17.0817.3216.7213,331
17.08+0.10+0.6%16.9817.1016.7011,524
16.98-0.38-2.2%17.4217.6016.7217,307
17.36-0.02-0.1%17.1017.3616.5248,909
17.38-0.30-1.7%17.6817.6817.1028,925
17.68-0.70-3.8%18.3018.3017.5821,035
18.380.000.0%18.3018.4818.088,043
18.38-0.12-0.6%18.2618.4618.0212,179
18.50+0.10+0.5%18.4018.5418.0037,983
18.40-0.40-2.1%18.9018.9018.1027,917
18.80+0.70+3.9%18.1018.8818.1036,665
18.10-0.32-1.7%18.6018.6017.3264,029
18.42-0.14-0.8%18.9219.3818.3038,418
18.56+0.34+1.9%18.3019.5818.24144,838
18.22+1.70+10.3%17.2018.4017.00140,275
16.52-0.38-2.2%17.0017.2816.5020,525
16.90-0.18-1.1%17.0017.0016.847,389
17.08-0.42-2.4%17.5017.5016.6257,021
17.50+0.06+0.3%17.5817.8417.2259,481
17.44+1.72+10.9%16.9417.8816.62256,599
15.72+0.14+0.9%15.7016.0015.5821,454
15.58-0.42-2.6%15.8015.9815.5022,997
16.00-0.02-0.1%16.2016.3015.8029,490
16.02+0.92+6.1%15.3016.1215.0064,271
15.10+0.28+1.9%14.8815.1014.6619,491
14.82+0.08+0.5%14.8015.0014.7212,959
14.74-0.18-1.2%15.0615.0614.6226,410
14.92-0.08-0.5%15.0015.0814.6618,067
Ticker
Lang & Schwarz:A1JUH2
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Lang & Schwarz
Currency
EUR

What changed lately

Latest news

Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update

May 16, 2024

Ryvu Therapeutics - Expansion of Clinical Development of RVU120 in Low-Risk Myelodysplastic Syndromes

Oct 23, 2023

Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Solid Tumors and AML/HR-MDS, and Presents the Updated Development Plan for RVU120

Oct 23, 2023

Ryvu Therapeutics Announces Closing of Equity Offering with Gross Proceeds Over PLN 250 Million

Dec 22, 2022

Ryvu Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 24, 2022

Ryvu Therapeutics Announces Poster Presentations at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium

Oct 12, 2022

Ryvu Therapeutics Announces Promotion of Hendrik Nogai and Vatnak Vat-Ho to the Management Board

Jul 26, 2022

All Ryvu Therapeutics SA news

Decks

Ryvu Therapeutics SA on 6ix

Sector
Health care
Industry
Biotechnology
News releases
7 in all · newest May 16, 2024 · oldest 2022
Decks
7 decks · latest September 2026

Where Ryvu Therapeutics SA is listed

ListingExchangeCountryCurrency
GPW:RVU · Home listingGPWPolandPLN
Lang & Schwarz:A1JUH2 · This pageLang & SchwarzGermanyEUR
LS Exchange:A1JUH2LS ExchangeGermanyEUR
LSE:0RKTLSEUnited KingdomPLN
Frankfurt:9Y4FrankfurtGermanyEUR
Stuttgart:9Y4StuttgartGermanyEUR
Dusseldorf:9Y4DusseldorfGermanyEUR

Log in to ask 6ix AI your own questions about Ryvu Therapeutics SA.